文献速递细菌感染、耐药与抗菌药物结核与非结核分枝杆菌

世卫组织耐药菌优先清单:新抗生素研发与结核防控方向

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.
PubMed 文献 · Lancet Infect Dis · 2017-12-21

世界卫生组织采用多准则决策分析法,对20种细菌的25种获得性耐药模式按10项准则评分,将耐药菌分为关键、高、中三级优先。关键优先包括碳青霉烯耐药鲍曼不动杆菌、铜绿假单胞菌及碳青霉烯/三代头孢耐药肠杆菌科;建议未来研发聚焦抗多重耐药结核与革兰阴性菌。

要点

  • 关键优先菌:碳青霉烯耐药鲍曼不动杆菌、铜绿假单胞菌及碳青霉烯/三代头孢耐药肠杆菌科。
  • 高优先包括万古霉素耐药屎肠球菌、甲氧西林耐药金黄色葡萄球菌。
  • 研发应聚焦抗多重耐药结核与革兰阴性菌,兼顾社区获得性耐药菌。

核心结论

  • 未来抗生素研发策略应聚焦对多重耐药结核和革兰阴性菌有效的药物。
  • 全球策略应纳入导致社区获得性感染的耐药菌,如沙门菌属、弯曲杆菌属、淋病奈瑟菌和幽门螺杆菌。

研究设计与样本

  • 采用多准则决策分析法,先确定相关准则,再对每种耐药菌评分。
  • 通过偏好调查获取专家对准则的权重,最终建立耐药菌优先排序。
  • 共纳入20种细菌、25种获得性耐药模式和10项优先评估准则。

主要发现

  • 10项准则包括死亡率、医疗负担、社区负担、耐药患病率、10年耐药趋势、传播性、社区可预防性、医疗环境可预防性、可治疗性和研发管线。
  • 以细菌总评分的第33百分位为截断值,将优先清单分为关键、高、中三级。
  • 关键优先菌包括碳青霉烯耐药鲍曼不动杆菌、碳青霉烯耐药铜绿假单胞菌、碳青霉烯耐药及三代头孢耐药肠杆菌科。
  • 高优先革兰阳性菌为万古霉素耐药屎肠球菌和甲氧西林耐药金黄色葡萄球菌。
  • 社区获得性感染相关的高优先菌包括克拉霉素耐药幽门螺杆菌、氟喹诺酮耐药弯曲杆菌属、淋病奈瑟菌和伤寒沙门菌。

关键数值与推荐

  • 优先清单分三级(关键、高、中),截断值为细菌总评分的第33百分位。
  • 关键优先:碳青霉烯耐药鲍曼不动杆菌和铜绿假单胞菌,碳青霉烯耐药及三代头孢耐药肠杆菌科。
  • 高优先:万古霉素耐药屎肠球菌、甲氧西林耐药金黄色葡萄球菌。
  • 高优先社区获得性耐药菌:克拉霉素耐药幽门螺杆菌、氟喹诺酮耐药弯曲杆菌属、淋病奈瑟菌、伤寒沙门菌。

临床怎么用

  • 临床可据此清单识别需重点防控和合理用药的关键耐药菌。
  • 研发与用药策略应优先覆盖多重耐药结核和革兰阴性菌。
  • 社区获得性感染经验治疗需关注沙门菌、弯曲杆菌、淋病奈瑟菌和幽门螺杆菌耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and mortality worldwide. Due to its large public health and societal implications, multidrug-resistant tuberculosis has been long regarded by WHO as a global priority for investment in new drugs. In 2016, WHO was requested by member states to create a priority list of other antibiotic-resistant bacteria to support research and development of effective drugs. METHODS: We used a multicriteria decision analysis method to prioritise antibiotic-resistant bacteria; this method involved the identification of relevant criteria to assess priority against which each antibiotic-resistant bacterium was rated. The final priority ranking of the antibiotic-resistant bacteria was established after a preference-based survey was used to obtain expert weighting of criteria. FINDINGS: We selected 20 bacterial species with 25 patterns of acquired resistance and ten criteria to assess priority: mortality, health-care burden, community burden, prevalence of resistance, 10-year trend of resistance, transmissibility, preventability in the community setting, preventability in the health-care setting, treatability, and pipeline. We stratified the priority list into three tiers (critical, high, and medium priority), using the 33rd percentile of the bacterium's total scores as the cutoff. Critical-priority bacteria included carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, and carbapenem-resistant and third-generation cephalosporin-resistant Enterobacteriaceae. The highest ranked Gram-positive bacteria (high priority) were vancomycin-resistant Enterococcus faecium and meticillin-resistant Staphylococcus aureus. Of the bacteria typically responsible for community-acquired infections, clarithromycin-resistant Helicobacter pylori, and fluoroquinolone-resistant Campylobacter spp, Neisseria gonorrhoeae, and Salmonella typhi were included in the high-priority tier. INTERPRETATION: Future development strategies should focus on antibiotics that are active against multidrug-resistant tuberculosis and Gram-negative bacteria. The global strategy should include antibiotic-resistant bacteria responsible for community-acquired infections such as Salmonella spp, Campylobacter spp, N gonorrhoeae, and H pylori. FUNDING: World Health Organization.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2017. PMID: 29276051. doi:10.1016/S1473-3099(17)30753-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。